Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenomedWAR:GEN -2.76%83 Equity-to-Asset is 0.74 as of Jun. 2026, which is 12% below its 10-year median of 0.84. GuruFocus rates WAR:GEN with a GF Score™ of 83/100 and a GF Value™ of zł36.37 (Fairly Valued). The stock has 5 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Genomed ranks better than 77.73% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Genomed's Total Stockholders Equity for the quarter that ended in Jun. 2026 was zł10.75 Mil. Genomed's Total Assets for the quarter that ended in Jun. 2026 was zł14.63 Mil.
Therefore, Genomed's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.74.
The historical rank and industry rank for Genomed's Equity-to-Asset or its related term are showing as below:
WAR:GEN'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.61 Med: 0.84 Max: 0.9
Current: 0.76
During the past 13 years, the highest Equity to Asset Ratio of Genomed was 0.90. The lowest was 0.61. And the median was 0.84.
WAR:GEN's Equity-to-Asset is ranked better than 77.73% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs WAR:GEN: 0.76
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Genomed Equity-to-Asset Related Terms
Genomed Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Genomed's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:GEN vs TMO, DHR, NTRA: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Genomed's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomed Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genomed's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Genomed's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Genomed's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomed (WAR:GEN) has a Equity-to-Asset of 0.74 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Genomed and its competitors. This is 12% below median its historical median of 0.84. Over the past decade, Genomed's Equity-to-Asset has ranged from 0.61 to 0.90. According to the industry distribution chart, Genomed ranks #47 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 22.3%.
Is Genomed's Equity-to-Asset too high?
Genomed's current Equity-to-Asset of 0.74 is 12% below median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 0.90. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Genomed's value of 0.74 is 25.4% above this industry median. Based on the distribution chart, Genomed ranks #47 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Genomed has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genomed's Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genomed ranks #47 out of 211 companies for Equity-to-Asset. This places Genomed in the top 22% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.59. Genomed's value of 0.74 is 25.4% above this benchmark. Historically, Genomed's own Equity-to-Asset has ranged from 0.61 to 0.90 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 0.59, Genomed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomed's current Equity-to-Asset of 0.74 is 25.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Genomed and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomed's current Equity-to-Asset is 0.74, which is 12% below median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Fairly Valued. The stock's GF Value™ is zł36.37, compared to a current price of zł35.20 — trading 3.2% below its estimated fair value. The current Equity-to-Asset is 0.74, which is 12% below median its 10-year median of 0.84 and 25.4% above the Medical Diagnostics & Research industry median of 0.59. Genomed's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Genomed (WAR:GEN), the current Equity-to-Asset is 0.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomed (WAR:GEN) Overvalued in 2026?
Based on GuruFocus' analysis, Genomed stock appears to be undervalued.
The current stock price of zł35.20 is trading 3.2% below its estimated GF Value™ of zł36.37.
GuruFocus considers Genomed to be Fairly Valued.
Key valuation signals for WAR:GEN:
Equity-to-Asset: 0.74 (12% below median its 10-year median of 0.84)
GF Value™: zł36.37 vs. price of zł35.20 (3.2% below fair value)
Industry Position: 25.4% above the Medical Diagnostics & Research median (#47 of 211)
No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
83GF Score
Get the complete analysis for WAR:GEN
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:GEN has been successfully added to your 
